Since 1939, when Alexander1developed specific type B anti-influenzal rabbit serum, interest in influenzal meningitis has been greatly intensified. Many reports of recoveries have been published during the past five years, and much has been written concerning this disease, which was formerly almost universally fatal.2Nevertheless, although sulfonamide compounds, specific serum and streptomycin are all valuable therapeutic aids, there is no standard accepted for their application. Those who make use of intrathecal treatment cling tenaciously to the method as an old established custom which cannot be relinquished. However, more than twelve years ago one3of us reported on the exclusive use of intravenous therapy for patients with meningitis and demonstrated its advantages, including lowered fatality rates,4when large doses of serum were injected and intrathecal therapy was abandoned. Although when first inaugurated this plan applied to meningococcic infections, it was soon found equally effective for all